YOLFTbeta
Shanghai Shen Lian Biomedical Corp

Shanghai Shen Lian Biomedical Corp

688098 · SHG · Healthcare / Biotechnology

6.93CNY-0.15 (-2.12%)

Price History

Full chart

Market Stats

Previous Close7.08
Open7.08
Day Range6.92 – 7.20
52-Week Range7.29 – 12.36
Volume1.80M
Market Cap3.47B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.07
Dividend Yield0.00%
Beta0.54
50-Day Avg8.33
200-Day Avg8.82

About

Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China. The company offers swine vaccines, ruminant vaccine, diagnostic reagents, and pet biological products. It also provides monoclonal antibody drug for HIV treatment, anti-allergy anti-IgE monoclonal antibody drug, and anti-herpes simplex virus monoclonal antibody drugs. In addition, the company offers foot-and-mouth disease vaccines for pigs, cattle, and sheep; and porcine circovirus type 2 subunit vaccines. Shanghai Shen Lian Biomedical Corporation was founded in 2001 and is headquartered in Shanghai, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Dongsheng Nie
  • Employees376
  • HeadquartersNo. 48 Jiangchuan East Road, Shanghai, China, 200241, China
  • Websitehttps://www.slbio.com.cn

Leadership

  • Mr. Dongsheng NieChairman of the Board of Directors and Director of R&D Center · b. 1960
  • Mr. Zhen ZhangEmployee Representative Director, GM & Core Technical Personnel · b. 1980
  • Mr. Xun LiuFinancial Director · b. 1991
  • Mr. Bo YinTechnical Director · b. 1983
  • Ms. Haixia YuBoard Secretary · b. 1985
  • Jie WuAccounting Supervisor
  • Mr. Gui Jun MaCore Technician of R&D Center · b. 1977

Financials

Income Statement

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue193.09M203.65M240.92M267.71M302.08M275.14M253.81M337.73M358.43M328.59M301.49M303.41M288.27M
Growth (%)-+5.47%+18.30%+11.12%+12.84%-8.92%-7.75%+33.07%+6.13%-8.32%-8.25%+0.64%-4.99%
Cost of Revenue42.28M44.49M51.26M58.38M60.59M54.59M44.96M55.10M87.01M81.38M87.89M120.62M124.47M
Gross Profit150.81M159.16M189.67M209.32M241.49M220.55M208.84M282.63M271.42M247.21M213.59M182.80M288.27M
Gross Margin78.10%78.15%78.72%78.19%79.94%80.16%82.28%83.69%75.72%75.23%70.85%60.25%100.00%
Operating Expense101.06M86.99M100.98M120.88M127.25M119.61M117.99M135.24M142.73M171.98M177.47M239.31M314.64M
Operating Income49.75M72.17M88.68M88.44M114.24M100.94M90.86M147.39M128.69M75.23M36.12M-56.51M-26.38M
Operating Margin25.77%35.44%36.81%33.04%37.82%36.69%35.80%43.64%35.90%22.90%11.98%-18.62%-9.15%
EBITDA60.03M85.98M95.95M100.97M124.98M113.22M105.85M170.77M169.62M144.16M99.45M11.11M42.85M
EBITDA Margin31.09%42.22%39.83%37.72%41.37%41.15%41.71%50.56%47.32%43.87%32.99%3.66%14.86%
Net Income41.82M61.14M75.84M73.47M98.68M87.58M77.96M129.51M110.20M61.10M31.52M-44.74M-19.09M
Net Income Margin21.66%30.02%31.48%27.45%32.67%31.83%30.71%38.35%30.75%18.59%10.45%-14.75%-6.62%
R&D10.91M11.92M12.66M16.75M16.65M21.29M26.56M31.91M34.95M39.04M44.53M49.36M44.81M
R&D as % of Total Revenue5.65%5.86%5.25%6.26%5.51%7.74%10.47%9.45%9.75%11.88%14.77%16.27%15.55%
Interest Expense531.80K1.20M29.87K227.04K127.22K36.02K36.82K27.16K20.59K25.03K35.94K76.75K532.06K
Interest Expense % of Total Revenue0.28%0.59%0.01%0.08%0.04%0.01%0.01%0.01%0.01%0.01%0.01%0.03%0.18%

Balance Sheet

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets531.53M528.89M490.32M607.79M692.19M1.01B1.45B1.51B1.60B1.61B1.59B1.55B1.54B
Total Liabilities203.94M287.32M172.90M142.32M142.92M181.18M166.33M118.20M125.48M108.21M86.93M128.50M143.41M
Total Equity327.59M241.57M317.41M465.47M549.27M831.94M1.28B1.40B1.48B1.50B1.49B1.41B1.39B
Cash221.95M117.63M136.52M165.34M145.98M384.31M155.86M114.61M44.21M52.74M44.98M146.21M122.00M
Total Debt--45.00M-27.75M30.00M30.02M652.02K513.89K445.96K1.25M15.01M-
Net Debt-221.95M-117.63M-91.52M-165.34M-118.24M-354.31M-125.84M-113.96M-43.70M-52.30M-43.72M-131.19M-

Cash Flow

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow51.79M105.98M30.86M48.00M74.61M121.13M53.81M111.73M90.12M9.09M3.53M89.36M33.08M
Investing Cash Flow25.27M-139.85M56.53M-76.52M-102.54M-77.45M-630.95M-90.10M-127.21M36.01M21.86M-3.68M-
Financing Cash Flow-9.95M-70.45M-68.50M28.76M11.90M196.27M371.59M-63.86M-32.30M-36.70M-33.14M-19.36M-
Capital Expenditure35.23M31.57M41.93M115.70M103.44M78.80M104.09M163.56M188.16M93.12M129.63M84.91M45.23M
Free Cash Flow16.55M74.41M-11.07M-67.71M-28.84M42.33M-50.28M-51.83M-98.04M-84.04M-126.11M4.45M-12.16M
Dividends Paid13.83M70.45M113.50M10.09M15.84M10.48M28.78M32.78M40.97M36.96M32.77M14.35M265.69K
FCF to OCF31.96%70.21%-35.87%-141.07%-38.65%34.94%-93.43%-46.39%-108.79%-924.67%-3576.95%4.98%-36.75%
Dividend Paid to FCF83.56%94.68%-1025.33%-14.91%-54.94%24.76%-57.24%-63.23%-41.79%-43.98%-25.99%322.29%-2.19%

Earnings

Report DateDec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Apr 28, 2022Aug 30, 2022Oct 26, 2022Feb 27, 2023Apr 26, 2023
EPS Estimate--------------
EPS Actual0.000.120.030.18-0.020.070.040.120.040.05-0.000.12-0.030.04
Surprise--------------
Timing---------Pre-marketAfter-hoursPre-marketAfter-hoursPre-market

Key Statistics & Ratios

Market Cap3.47B
Enterprise Value3.55B
Trailing P/E0.00
Forward P/E0.00
Price / Sales12.48
Price / Book2.57
EPS-0.07
Book Value3.38
Revenue (TTM)278.46M
Gross Profit (TTM)156.41M
EBITDA38.70M
Profit Margin-9.61%
Operating Margin-41.11%
Return on Equity-2.16%
Return on Assets-1.36%
Shares Outstanding410.64M
Shares Float222.79M
Beta0.54
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20231×
0.08Jun 13, 2023
20221×
0.09Jun 10, 2022
20211×
0.10Jun 10, 2021
20201×
0.08Jun 8, 2020